Inhibition of Salmonella Enterica Serovar Typhimurium Type Ⅲ Secretion System and Infection Using Small Molecule Quercitrin

Qingjie Li,Lianping Wang,Shuang Liu,Jingwen Xu,Zeyu Song,Tingting Chen,Xuming Deng,Qianghua Lv
DOI: https://doi.org/10.21203/rs.3.rs-1129712/v1
2021-01-01
Abstract:AimsThis study was conducted to screen the type Ⅲ secretion system (T3SS) inhibitors of Salmonella enterica serovar Typhimurium (S. Typhimurium) from natural compounds. Through systemic analysis the pharmacological activity and action mechanism of candidate compounds in vivo and in vitro. Methods and resultsUsing an effector-β-lactamase fusion reporter system in S. Typhimurium, we discovered that quercitrin could block effector SipA translocation into eukaryotic host cell without affecting bacterial growth, and inhibit invasion or epithelial cells damage. Using β-galactosidase activity and Western blot assay, it was found that quercitrin significantly inhibits the expression of SPI-1 genes (hilA and sopA) and effectors (SipA and SipC). The animal experiment results indicated that quercitrin reduces mortality, pathological damages and colony colonization of infected mice. ConclusionsSmall-molecule inhibitor quercitrin directly inhibits the founction of T3SS in S. Typhimurium, and provids a potential alternative antimicrobial against Salmonella infection.Significance and impact of the studyNatural compounds have become valuable resources for antibacterials discovery due to their widely structures and biological activities. However, the potential targets and molecular action mechanisms of candidate compounds responsible for anti-infections remain elusive. The T3SS plays a crucial role in bacterial invasion and pathogenesis process in S. Typhimurium. Compared with traditional antibiotics, small molecular compounds can inhibit the T3SS of Salmonella and achieve the effect of anti-infection. They have less pressure on bacterial survival and are not easy to produce drug resistance. This provides strong evidence for development novel anti-virulence drugs against Salmonella infection.
What problem does this paper attempt to address?